Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.54 |
| ▸ | NMT2 | O60551 | 2/20 | 0.49 |
| ▸ | NMT1 | P30419 | 2/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
| ▸ | FURIN | P09958 | 4/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29626727 | 0.97 | CTSL (0.58) | CTSLSLC6A5NMT2NMT1TLR2 | |
| SCHEMBL29520919 | 0.93 | SLC6A5 (0.64) | CTSLSLC6A5NMT2NMT1TLR2 | |
| SCHEMBL3121566 | 0.93 | SLC6A5 (0.60) | CTSLSLC6A5NMT2NMT1TLR2 | |
| SCHEMBL28627441 | 0.93 | SLC6A5 (0.62) | CTSLSLC6A5NMT2NMT1TLR2 | |
| SCHEMBL1032838 | 0.93 | SLC6A5 (0.62) | CTSLSLC6A5NMT2NMT1TLR2 | |
| SCHEMBL445569 | 0.91 | SLC6A5 (0.66) | CTSLSLC6A5NMT2NMT1TLR2 | |
| SCHEMBL443317 | 0.91 | SLC6A5 (0.66) | CTSLSLC6A5NMT2NMT1TLR2 | |
| SCHEMBL23227556 | 0.90 | CTSL (0.56) | CTSLSLC6A5NMT2NMT1TLR2 | |
| SCHEMBL5604836 | 0.89 | SLC6A5 (0.65) | CTSLSLC6A5NMT2NMT1TLR2 | |
| SCHEMBL31307671 | 0.89 | SLC6A5 (0.57) | CTSLSLC6A5NMT2NMT1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152494-A1 | COSMETIC COMPOSITION CONTAINING RETINOID, EXTRACT OF CENTELLA ASIATICA AND A DIPEPTIDE | THE BOOTS COMPANY PLC (GB) | 2025-05-15 | — | — | US | claimed |
| EP-4479021-A1 | COSMETIC COMPOSITION CONTAINING RETINOID, EXTRACT OF CENTELLA ASIATICA AND A DIPEPTIDE | The Boots Company PLC (GB) | 2024-12-25 | — | — | EP | claimed |
| WO-2023156072-A1 | COSMETIC COMPOSITION CONTAINING RETINOID, EXTRACT OF CENTELLA ASIATICA AND A DIPEPTIDE | THE BOOTS COMPANY PLC (GB) | 2023-08-24 | — | — | WO | claimed |
| US-12594227-B2 | Tetrapeptide and compositions comprising tetrapeptides | THE BOOTS COMPANY PLC (GB) | 2026-04-07 | — | — | US | disclosed |
| WO-2026046854-A1 | PEPTIDE CONTAINING HYDROGEL COMPOSITIONS | THE BOOTS COMPANY PLC (GB) | 2026-03-05 | — | — | WO | disclosed |
| US-20260049116-A1 | T-Cell Modulatory Multimeric Polypeptides and Methods of Use Thereof | CUE BIOPHARMA INC (US) | 2026-02-19 | — | — | US | disclosed |
| WO-2025252800-A1 | NOVEL PEPTIDE COMPOSITIONS | DSM IP ASSETS B.V. (NL) | 2025-12-11 | — | — | WO | disclosed |
| WO-2025215346-A1 | SKIN WOUND TREATMENT | THE BOOTS COMPANY PLC (GB) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025215348-A1 | SKIN WOUND TREATMENT | THE BOOTS COMPANY PLC (GB) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025215347-A1 | SKIN WOUND TREATMENT | THE BOOTS COMPANY PLC (GB) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025215349-A1 | HAIR GROWTH RESTORATION | THE BOOTS COMPANY PLC (GB) | 2025-10-16 | — | — | WO | disclosed |
| WO-2022106054-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | THE BOOTS COMPANY PLC (GB) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022106056-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | THE BOOTS COMPANY PLC (GB) | 2022-05-27 | — | — | WO | disclosed |
| EP-4001294-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | The Boots Company plc (GB) | 2022-05-25 | — | — | EP | disclosed |
| EP-4000597-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | The Boots Company plc (GB) | 2022-05-25 | — | — | EP | disclosed |
| EP-4000598-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | The Boots Company plc (GB) | 2022-05-25 | — | — | EP | disclosed |
| EP-4000596-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | The Boots Company plc (GB) | 2022-05-25 | — | — | EP | disclosed |
| EP-4000595-A1 | TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES | The Boots Company plc (GB) | 2022-05-25 | — | — | EP | disclosed |
| CN-107567329-B | Fermented extract of eupenicillium crustaceum and cosmetic use thereof | 路博润先进材料公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20220089681-A1 | METHODS FOR MODULATING AN IMMUNE RESPONSE | CUE BIOPHARMA, INC. | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594227-B2 | Tetrapeptide and compositions comprising tetrapeptides | SRRM2, SGTA, QARS1 | CTSL 1747/4885SLC6A5 3227/4885NMT2 151/4885 |
| US-20260049116-A1 | T-Cell Modulatory Multimeric Polypeptides and Methods of Use Thereof | IL2, IL2RA, MICA | CTSL 532/4885SLC6A5 4436/4885NMT2 2023/4885 |
| US-20250152494-A1 | COSMETIC COMPOSITION CONTAINING RETINOID, EXTRACT OF CENTELLA ASIATICA AND A DIPEPTIDE | RARA, RARG, RARB | CTSL 1615/4885SLC6A5 4666/4885NMT2 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.